Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.92
-0.23 (-2.82%)
Jun 16, 2026, 4:00 PM EDT - Market closed
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
130
Market Cap
479.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 180.25M |
| Sutro Biopharma | 99.61M |
| Arvinas | 89.40M |
| 4D Molecular Therapeutics | 88.24M |
| Assembly Biosciences | 71.10M |
| Neurogene | 925.00K |
KYTX News
- 13 days ago - Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 13 days ago - Kyverna Therapeutics presents updated COMPARE trial data at EULAR - TheFly
- 13 days ago - Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis - GlobeNewsWire
- 13 days ago - Kyverna Therapeutics Slides: Corporate presentation - Filings
- 20 days ago - Kyverna Therapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 4 weeks ago - Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed - TheFly
- 4 weeks ago - Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - GlobeNewsWire